FDA expedited approval and implications for rational formulary and health plan design.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33908272.
- Also identified by DOI 10.18553/jmcp.2021.27.5.682 and PMC identifier 10391045.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
<b>DISCLOSURES:</b> No funding supported this commentary. The authors are employed by Humana, Inc. Shrank reports board of directors work for GetWell Network and NCQA. The other authors have nothing to disclose.
Medical subject headings
- Drug Approval
- Formularies as Topic
- Insurance, Pharmaceutical Services